Physician profile
Julius Shulman
NPI 1841294584
$3,402.16
in general payments reported to CMS, 2019-2025
21 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $292 · 2021: $158 · 2022: $905 · 2023: $732 · 2024: $567 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $973.42 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $690.38 | 2019-2025 | Clareon, Simbrinza, Argos |
| Coopervision INC. | $187.29 | 2022-2023 | Paragon Crt, Myday Contact Lens, Onefit Contact Lens |
| Novartis Pharmaceuticals Corporation | $180.56 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $179.75 | 2019-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $166.70 | 2022-2025 | Infuse, Prolensa, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $145.65 | 2019-2025 | Acuvue |
| Allergan, INC. | $143.19 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.91 | 2019-2021 | |
| Amgen INC. | $96.13 | 2024 | Tepezza |
| Sight Sciences, INC. | $75.37 | 2022 | |
| Apellis Pharmaceuticals, INC. | $69.32 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $63.17 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $60.71 | 2021-2022 | |
| Abbvie INC. | $58.58 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $55.70 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $50.11 | 2022 | |
| Kala Pharmaceuticals, INC. | $43.69 | 2019-2022 | |
| Thea Pharma INC. | $24.86 | 2025 | Iyuzeh |
| Shire North American Group INC | $19.63 | 2019 | |
| Dompe US, INC. | $16.04 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.